Drug intelligence / Profile preview

NMB

Development stage: Preclinical
Lead developer: NemaGen Discoveries
Modality: Peptides
Administration: Intravenous, Intramuscular, Intraosseous, Intraperitoneal, Intranasal, Inhalation, Topical, Buccal, Sublingual, Subcutaneous

Overview

NMB is a peptide-based therapeutic candidate developed by NemaGen Discoveries that targets neuromedin B (NMB). Currently in the preclinical stage, it is being investigated for the treatment of lung inflammation and chronic obstructive pulmonary disease (COPD). Neuromedin B is a member of the bombesin-like peptide family and is involved in regulating various physiological processes, including respiratory smooth muscle contraction and inflammatory signaling pathways. The therapeutic is designed to modulate NMB activity to reduce pulmonary inflammation and improve outcomes in patients with chronic respiratory disorders.

Other names: neuromedin B peptide

Targets

NMB (Neuromedin B)

Beyond the preview

Go deeper on NMB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMB.

Explore the full profile